FY2027 EPS Estimates for Ardelyx Lowered by HC Wainwright

Key Points

• HC Wainwright lowered Ardelyx’s FY2027 EPS estimate to $0.35 from $0.36 but maintained a Buy rating and $13 price target; it forecasts FY2028 EPS of $0.66.
• Ardelyx’s second-quarter loss of $0.07 per share exceeded the expected $0.05 loss, while revenue rose 34.3% year over year to $120.88 million but narrowly missed estimates.
• Analyst sentiment remains broadly positive, with a “Moderate Buy” consensus and average price target of $15.30, despite recent target cuts and a Strong Sell rating from Zacks.

Ardelyx, Inc. (NASDAQ:ARDX - Free Report) - Research analysts at HC Wainwright reduced their FY2027 EPS estimates for shares of Ardelyx in a research note issued to investors on Friday, August 7th. HC Wainwright analyst M. Caufield now anticipates that the biopharmaceutical company will earn $0.35 per share for the year, down from their previous estimate of $0.36. HC Wainwright has a "Buy" rating and a $13.00 price objective on the stock. The consensus estimate for Ardelyx's current full-year earnings is ($0.10) per share. HC Wainwright also issued estimates for Ardelyx's FY2028 earnings at $0.66 EPS.

ARDX has been the topic of a number of other research reports. Weiss Ratings lowered Ardelyx from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Monday, June 29th. Zacks Research downgraded Ardelyx from a "hold" rating to a "strong sell" rating in a research report on Wednesday, July 22nd. TD Cowen cut their price objective on Ardelyx from $13.00 to $10.00 and set a "buy" rating on the stock in a research note on Friday. BTIG Research cut their price objective on Ardelyx from $17.00 to $14.00 and set a "buy" rating on the stock in a research note on Friday. Finally, LADENBURG THALM/SH SH assumed coverage on Ardelyx in a report on Tuesday, June 16th. They issued a "buy" rating and a $16.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and two have given a Sell rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $15.30.

Ardelyx Stock Performance

NASDAQ ARDX opened at $4.00 on Monday. The company has a market capitalization of $996.76 million, a price-to-earnings ratio of -18.18 and a beta of 0.70. The company has a quick ratio of 3.28, a current ratio of 3.49 and a debt-to-equity ratio of 1.37. Ardelyx has a twelve month low of $3.90 and a twelve month high of $8.40. The stock has a fifty day simple moving average of $5.37 and a 200 day simple moving average of $6.07.

Ardelyx (NASDAQ:ARDX - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.07) EPS for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.02). Ardelyx had a negative return on equity of 35.57% and a negative net margin of 12.35%.The business had revenue of $120.88 million for the quarter, compared to analyst estimates of $121.03 million. During the same quarter last year, the firm posted ($0.08) EPS. Ardelyx's revenue for the quarter was up 34.3% on a year-over-year basis.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. BlackRock Inc. acquired a new position in Ardelyx during the 2nd quarter valued at about $119,874,000. AIGH Capital Management LLC purchased a new stake in shares of Ardelyx in the second quarter worth approximately $16,320,000. Bank of America Corp DE raised its stake in shares of Ardelyx by 88.8% in the second quarter. Bank of America Corp DE now owns 5,527,988 shares of the biopharmaceutical company's stock worth $21,670,000 after purchasing an additional 2,600,080 shares during the last quarter. State Street Corp lifted its holdings in shares of Ardelyx by 22.6% in the fourth quarter. State Street Corp now owns 11,912,339 shares of the biopharmaceutical company's stock valued at $69,449,000 after purchasing an additional 2,193,649 shares in the last quarter. Finally, Rubric Capital Management LP bought a new position in shares of Ardelyx in the first quarter valued at approximately $11,147,000. Institutional investors and hedge funds own 58.92% of the company's stock.

Insider Activity at Ardelyx

In other news, insider Mike Kelliher sold 7,248 shares of the business's stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $6.27, for a total transaction of $45,444.96. Following the completion of the sale, the insider owned 357,418 shares in the company, valued at $2,241,010.86. The trade was a 1.99% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Eric Duane Foster sold 7,998 shares of the company's stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $6.27, for a total value of $50,147.46. Following the transaction, the insider directly owned 417,972 shares in the company, valued at $2,620,684.44. The trade was a 1.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 24,572 shares of company stock valued at $154,066. Corporate insiders own 5.30% of the company's stock.

Key Ardelyx News

Here are the key news stories impacting Ardelyx this week:

• Positive Sentiment: Second-quarter revenue increased 34.3% year over year to approximately $120.9 million, indicating continued commercial growth despite missing the revenue estimate slightly. Ardelyx Reports Second Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: BTIG Research maintained a Buy rating on ARDX, suggesting substantial long-term upside potential even after reducing its price target from $17 to $14. BTIG Research price target update
• Neutral Sentiment: Ardelyx’s Q2 earnings call and business update provided additional discussion of operating performance and company priorities, but the available report does not identify a specific new catalyst driving the stock. Ardelyx Q2 2026 Earnings Call Transcript
• Negative Sentiment: Ardelyx reported a second-quarter loss of $0.07 per share, worse than the expected loss of $0.05, although it improved from a $0.08 loss in the year-ago quarter. Revenue of $120.88 million also narrowly missed estimates of approximately $121.0 million. Ardelyx Reports Q2 Loss, Lags Revenue Estimates
• Negative Sentiment: Zacks added ARDX to its Rank #5, or Strong Sell, list, adding to near-term pressure from the earnings miss and the company’s continuing negative profitability metrics. New Strong Sell Stocks for August 7th
• Negative Sentiment: The lower BTIG price target reflects reduced near-term expectations, even though the firm retained its Buy rating. BTIG Research price target update

About Ardelyx

Ardelyx, Inc NASDAQ: ARDX is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing targeted small molecule drugs for cardio‐renal and gastrointestinal diseases. The company's lead marketed product, tenapanor (sold under the brand name XPHOZAH in the United States), is approved for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. Ardelyx's proprietary approach targets epithelial transporters in the gastrointestinal tract, offering localized activity with limited systemic exposure.

Beyond tenapanor, Ardelyx's development pipeline includes treatments designed to address other complications in kidney disease and related metabolic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source